nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Methylprednisolone—multiple sclerosis	0.0849	0.124	CbGbCtD
Tolvaptan—CYP3A4—Fingolimod—multiple sclerosis	0.0789	0.115	CbGbCtD
Tolvaptan—ABCB1—Mitoxantrone—multiple sclerosis	0.0619	0.0901	CbGbCtD
Tolvaptan—ABCB1—Betamethasone—multiple sclerosis	0.0552	0.0803	CbGbCtD
Tolvaptan—ABCB1—Prednisolone—multiple sclerosis	0.0545	0.0793	CbGbCtD
Tolvaptan—ABCB1—Prednisone—multiple sclerosis	0.0514	0.0749	CbGbCtD
Tolvaptan—CYP3A4—Methylprednisolone—multiple sclerosis	0.0509	0.074	CbGbCtD
Tolvaptan—CYP3A4—Triamcinolone—multiple sclerosis	0.0385	0.0561	CbGbCtD
Tolvaptan—CYP3A4—Mitoxantrone—multiple sclerosis	0.0371	0.054	CbGbCtD
Tolvaptan—CYP3A4—Betamethasone—multiple sclerosis	0.0331	0.0481	CbGbCtD
Tolvaptan—CYP3A4—Prednisolone—multiple sclerosis	0.0326	0.0475	CbGbCtD
Tolvaptan—ABCB1—Dexamethasone—multiple sclerosis	0.0321	0.0467	CbGbCtD
Tolvaptan—CYP3A4—Prednisone—multiple sclerosis	0.0308	0.0449	CbGbCtD
Tolvaptan—ABCB1—Methotrexate—multiple sclerosis	0.0258	0.0376	CbGbCtD
Tolvaptan—CYP3A4—Dexamethasone—multiple sclerosis	0.0192	0.028	CbGbCtD
Tolvaptan—Blood uric acid increased—Mitoxantrone—multiple sclerosis	0.00151	0.00871	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00147	0.00849	CcSEcCtD
Tolvaptan—Hyperkalaemia—Mitoxantrone—multiple sclerosis	0.00146	0.00841	CcSEcCtD
Tolvaptan—Nervous system disorder—Fingolimod—multiple sclerosis	0.0014	0.00804	CcSEcCtD
Tolvaptan—Skin disorder—Fingolimod—multiple sclerosis	0.00138	0.00796	CcSEcCtD
Tolvaptan—Ecchymosis—Mitoxantrone—multiple sclerosis	0.00134	0.00774	CcSEcCtD
Tolvaptan—Renal failure—Cladribine—multiple sclerosis	0.00124	0.00716	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00123	0.00707	CcSEcCtD
Tolvaptan—Deep vein thrombosis—Methotrexate—multiple sclerosis	0.00122	0.00701	CcSEcCtD
Tolvaptan—Urinary tract disorder—Cladribine—multiple sclerosis	0.00112	0.00646	CcSEcCtD
Tolvaptan—Connective tissue disorder—Cladribine—multiple sclerosis	0.00112	0.00642	CcSEcCtD
Tolvaptan—Urethral disorder—Cladribine—multiple sclerosis	0.00111	0.00641	CcSEcCtD
Tolvaptan—Ecchymosis—Prednisolone—multiple sclerosis	0.0011	0.00635	CcSEcCtD
Tolvaptan—Hyponatraemia—Mitoxantrone—multiple sclerosis	0.00108	0.00624	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Mitoxantrone—multiple sclerosis	0.00108	0.00621	CcSEcCtD
Tolvaptan—Cardiac disorder—Cladribine—multiple sclerosis	0.00105	0.00607	CcSEcCtD
Tolvaptan—Angiopathy—Cladribine—multiple sclerosis	0.00103	0.00593	CcSEcCtD
Tolvaptan—Immune system disorder—Cladribine—multiple sclerosis	0.00103	0.00591	CcSEcCtD
Tolvaptan—Mediastinal disorder—Cladribine—multiple sclerosis	0.00102	0.00589	CcSEcCtD
Tolvaptan—Asthenia—Fingolimod—multiple sclerosis	0.00102	0.00588	CcSEcCtD
Tolvaptan—Ecchymosis—Triamcinolone—multiple sclerosis	0.00101	0.00584	CcSEcCtD
Tolvaptan—Ecchymosis—Methylprednisolone—multiple sclerosis	0.00101	0.00582	CcSEcCtD
Tolvaptan—Blood creatinine increased—Mitoxantrone—multiple sclerosis	0.00101	0.00582	CcSEcCtD
Tolvaptan—Pruritus—Fingolimod—multiple sclerosis	0.00101	0.0058	CcSEcCtD
Tolvaptan—Dehydration—Mitoxantrone—multiple sclerosis	0.001	0.00578	CcSEcCtD
Tolvaptan—Malnutrition—Cladribine—multiple sclerosis	0.000988	0.00569	CcSEcCtD
Tolvaptan—Diarrhoea—Fingolimod—multiple sclerosis	0.000974	0.00561	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000971	0.00559	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000951	0.00548	CcSEcCtD
Tolvaptan—Dizziness—Fingolimod—multiple sclerosis	0.000941	0.00542	CcSEcCtD
Tolvaptan—Ecchymosis—Betamethasone—multiple sclerosis	0.00092	0.0053	CcSEcCtD
Tolvaptan—Ecchymosis—Dexamethasone—multiple sclerosis	0.00092	0.0053	CcSEcCtD
Tolvaptan—Ill-defined disorder—Cladribine—multiple sclerosis	0.000917	0.00528	CcSEcCtD
Tolvaptan—Headache—Fingolimod—multiple sclerosis	0.000891	0.00513	CcSEcCtD
Tolvaptan—Malaise—Cladribine—multiple sclerosis	0.000891	0.00513	CcSEcCtD
Tolvaptan—Hyperglycaemia—Mitoxantrone—multiple sclerosis	0.000841	0.00484	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000836	0.00481	CcSEcCtD
Tolvaptan—Immune system disorder—Azathioprine—multiple sclerosis	0.000834	0.0048	CcSEcCtD
Tolvaptan—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000832	0.00479	CcSEcCtD
Tolvaptan—Discomfort—Cladribine—multiple sclerosis	0.000831	0.00479	CcSEcCtD
Tolvaptan—Renal failure—Mitoxantrone—multiple sclerosis	0.000817	0.00471	CcSEcCtD
Tolvaptan—Ecchymosis—Prednisone—multiple sclerosis	0.000801	0.00461	CcSEcCtD
Tolvaptan—Hyperuricaemia—Methotrexate—multiple sclerosis	0.000798	0.0046	CcSEcCtD
Tolvaptan—Nervous system disorder—Cladribine—multiple sclerosis	0.000791	0.00456	CcSEcCtD
Tolvaptan—Skin disorder—Cladribine—multiple sclerosis	0.000783	0.00451	CcSEcCtD
Tolvaptan—Anorexia—Cladribine—multiple sclerosis	0.000769	0.00443	CcSEcCtD
Tolvaptan—Blood uric acid increased—Methotrexate—multiple sclerosis	0.000754	0.00434	CcSEcCtD
Tolvaptan—Respiratory failure—Methotrexate—multiple sclerosis	0.000754	0.00434	CcSEcCtD
Tolvaptan—Ill-defined disorder—Azathioprine—multiple sclerosis	0.000746	0.00429	CcSEcCtD
Tolvaptan—Pulmonary embolism—Methotrexate—multiple sclerosis	0.00074	0.00426	CcSEcCtD
Tolvaptan—Breast disorder—Methylprednisolone—multiple sclerosis	0.000734	0.00423	CcSEcCtD
Tolvaptan—Malaise—Azathioprine—multiple sclerosis	0.000725	0.00417	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000716	0.00412	CcSEcCtD
Tolvaptan—Decreased appetite—Cladribine—multiple sclerosis	0.000701	0.00404	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000696	0.00401	CcSEcCtD
Tolvaptan—Constipation—Cladribine—multiple sclerosis	0.00069	0.00397	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000679	0.00391	CcSEcCtD
Tolvaptan—Discomfort—Azathioprine—multiple sclerosis	0.000676	0.00389	CcSEcCtD
Tolvaptan—Urine output increased—Methotrexate—multiple sclerosis	0.000669	0.00385	CcSEcCtD
Tolvaptan—Ecchymosis—Methotrexate—multiple sclerosis	0.000669	0.00385	CcSEcCtD
Tolvaptan—Feeling abnormal—Cladribine—multiple sclerosis	0.000665	0.00383	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Prednisone—multiple sclerosis	0.000643	0.0037	CcSEcCtD
Tolvaptan—Body temperature increased—Cladribine—multiple sclerosis	0.000638	0.00367	CcSEcCtD
Tolvaptan—Skin disorder—Azathioprine—multiple sclerosis	0.000637	0.00367	CcSEcCtD
Tolvaptan—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000636	0.00366	CcSEcCtD
Tolvaptan—Polyuria—Methotrexate—multiple sclerosis	0.000612	0.00352	CcSEcCtD
Tolvaptan—Ill-defined disorder—Mitoxantrone—multiple sclerosis	0.000603	0.00347	CcSEcCtD
Tolvaptan—Hypersensitivity—Cladribine—multiple sclerosis	0.000594	0.00342	CcSEcCtD
Tolvaptan—Malaise—Mitoxantrone—multiple sclerosis	0.000586	0.00337	CcSEcCtD
Tolvaptan—Asthenia—Cladribine—multiple sclerosis	0.000579	0.00333	CcSEcCtD
Tolvaptan—Hyperglycaemia—Dexamethasone—multiple sclerosis	0.000576	0.00332	CcSEcCtD
Tolvaptan—Hyperglycaemia—Betamethasone—multiple sclerosis	0.000576	0.00332	CcSEcCtD
Tolvaptan—Pruritus—Cladribine—multiple sclerosis	0.000571	0.00329	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000567	0.00327	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000566	0.00326	CcSEcCtD
Tolvaptan—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000552	0.00318	CcSEcCtD
Tolvaptan—Diarrhoea—Cladribine—multiple sclerosis	0.000552	0.00318	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Methotrexate—multiple sclerosis	0.000548	0.00316	CcSEcCtD
Tolvaptan—Discomfort—Mitoxantrone—multiple sclerosis	0.000546	0.00315	CcSEcCtD
Tolvaptan—Feeling abnormal—Azathioprine—multiple sclerosis	0.00054	0.00311	CcSEcCtD
Tolvaptan—Dizziness—Cladribine—multiple sclerosis	0.000533	0.00307	CcSEcCtD
Tolvaptan—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.00053	0.00305	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000527	0.00378	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000523	0.00375	CbGpPWpGaD
Tolvaptan—Shock—Mitoxantrone—multiple sclerosis	0.000522	0.003	CcSEcCtD
Tolvaptan—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000521	0.003	CcSEcCtD
Tolvaptan—Body temperature increased—Azathioprine—multiple sclerosis	0.000518	0.00299	CcSEcCtD
Tolvaptan—Skin disorder—Mitoxantrone—multiple sclerosis	0.000515	0.00297	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000513	0.00369	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000513	0.00369	CbGpPWpGaD
Tolvaptan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.00051	0.00366	CbGpPWpGaD
Tolvaptan—Angiopathy—Methylprednisolone—multiple sclerosis	0.00051	0.00294	CcSEcCtD
Tolvaptan—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000507	0.00292	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000506	0.00292	CcSEcCtD
Tolvaptan—Anorexia—Mitoxantrone—multiple sclerosis	0.000505	0.00291	CcSEcCtD
Tolvaptan—Headache—Cladribine—multiple sclerosis	0.000505	0.00291	CcSEcCtD
Tolvaptan—Hyperglycaemia—Prednisone—multiple sclerosis	0.000501	0.00289	CcSEcCtD
Tolvaptan—Ill-defined disorder—Prednisolone—multiple sclerosis	0.000494	0.00285	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000491	0.00352	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL3—multiple sclerosis	0.00049	0.00352	CbGpPWpGaD
Tolvaptan—Malnutrition—Methylprednisolone—multiple sclerosis	0.000489	0.00282	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCL3—multiple sclerosis	0.000486	0.00349	CbGpPWpGaD
Tolvaptan—Breast disorder—Methotrexate—multiple sclerosis	0.000486	0.0028	CcSEcCtD
Tolvaptan—Hypersensitivity—Azathioprine—multiple sclerosis	0.000483	0.00278	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000483	0.00347	CbGpPWpGaD
Tolvaptan—Malaise—Prednisolone—multiple sclerosis	0.000481	0.00277	CcSEcCtD
Tolvaptan—Dysgeusia—Triamcinolone—multiple sclerosis	0.00048	0.00276	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00048	0.00344	CbGpPWpGaD
Tolvaptan—Nausea—Cladribine—multiple sclerosis	0.000479	0.00276	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—S1PR1—multiple sclerosis	0.000478	0.00343	CbGpPWpGaD
Tolvaptan—Syncope—Prednisolone—multiple sclerosis	0.000478	0.00275	CcSEcCtD
Tolvaptan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000476	0.00341	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—S1PR1—multiple sclerosis	0.000475	0.00341	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—PTGER4—multiple sclerosis	0.000471	0.00338	CbGpPWpGaD
Tolvaptan—Loss of consciousness—Prednisolone—multiple sclerosis	0.000468	0.0027	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—PTGER4—multiple sclerosis	0.000468	0.00336	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000467	0.00335	CbGpPWpGaD
Tolvaptan—Angiopathy—Dexamethasone—multiple sclerosis	0.000463	0.00267	CcSEcCtD
Tolvaptan—Angiopathy—Betamethasone—multiple sclerosis	0.000463	0.00267	CcSEcCtD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000461	0.00331	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000461	0.00331	CbGpPWpGaD
Tolvaptan—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000461	0.00265	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCR3—multiple sclerosis	0.000455	0.00327	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000455	0.00262	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000454	0.00261	CcSEcCtD
Tolvaptan—Constipation—Mitoxantrone—multiple sclerosis	0.000453	0.00261	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CXCR3—multiple sclerosis	0.000452	0.00324	CbGpPWpGaD
Tolvaptan—Diarrhoea—Azathioprine—multiple sclerosis	0.000449	0.00258	CcSEcCtD
Tolvaptan—Discomfort—Prednisolone—multiple sclerosis	0.000448	0.00258	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—RGS1—multiple sclerosis	0.000448	0.00322	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—RGS1—multiple sclerosis	0.000445	0.00319	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CCR2—multiple sclerosis	0.000443	0.00318	CbGpPWpGaD
Tolvaptan—Malaise—Triamcinolone—multiple sclerosis	0.000442	0.00255	CcSEcCtD
Tolvaptan—Malaise—Methylprednisolone—multiple sclerosis	0.000441	0.00254	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.00044	0.00316	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CCR2—multiple sclerosis	0.00044	0.00316	CbGpPWpGaD
Tolvaptan—Syncope—Triamcinolone—multiple sclerosis	0.00044	0.00253	CcSEcCtD
Tolvaptan—Syncope—Methylprednisolone—multiple sclerosis	0.000439	0.00253	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000437	0.00314	CbGpPWpGaD
Tolvaptan—Connective tissue disorder—Prednisone—multiple sclerosis	0.000437	0.00252	CcSEcCtD
Tolvaptan—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000437	0.00252	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000436	0.00313	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000435	0.0025	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000434	0.00312	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000434	0.00312	CbGpPWpGaD
Tolvaptan—Dizziness—Azathioprine—multiple sclerosis	0.000434	0.0025	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000433	0.00311	CbGpPWpGaD
Tolvaptan—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000431	0.00248	CcSEcCtD
Tolvaptan—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.00043	0.00248	CcSEcCtD
Tolvaptan—Shock—Prednisolone—multiple sclerosis	0.000428	0.00246	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000427	0.00307	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—GPR65—multiple sclerosis	0.000424	0.00305	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000424	0.00304	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—GPR65—multiple sclerosis	0.000421	0.00303	CbGpPWpGaD
Tolvaptan—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000419	0.00241	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000416	0.00299	CbGpPWpGaD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000413	0.00238	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000413	0.00296	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000413	0.00238	CcSEcCtD
Tolvaptan—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000413	0.00238	CcSEcCtD
Tolvaptan—Discomfort—Triamcinolone—multiple sclerosis	0.000412	0.00237	CcSEcCtD
Tolvaptan—Discomfort—Methylprednisolone—multiple sclerosis	0.000411	0.00237	CcSEcCtD
Tolvaptan—Headache—Azathioprine—multiple sclerosis	0.000411	0.00237	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CNR1—multiple sclerosis	0.000409	0.00293	CbGpPWpGaD
Tolvaptan—Dry mouth—Triamcinolone—multiple sclerosis	0.000408	0.00235	CcSEcCtD
Tolvaptan—Renal failure—Methotrexate—multiple sclerosis	0.000407	0.00234	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—RGS1—multiple sclerosis	0.000407	0.00292	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CNR1—multiple sclerosis	0.000406	0.00291	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—RGS1—multiple sclerosis	0.000404	0.0029	CbGpPWpGaD
Tolvaptan—Angiopathy—Prednisone—multiple sclerosis	0.000404	0.00232	CcSEcCtD
Tolvaptan—Immune system disorder—Prednisone—multiple sclerosis	0.000402	0.00231	CcSEcCtD
Tolvaptan—Malaise—Betamethasone—multiple sclerosis	0.000401	0.00231	CcSEcCtD
Tolvaptan—Malaise—Dexamethasone—multiple sclerosis	0.000401	0.00231	CcSEcCtD
Tolvaptan—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.0004	0.0023	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.0004	0.00287	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000399	0.0023	CcSEcCtD
Tolvaptan—Syncope—Betamethasone—multiple sclerosis	0.000399	0.0023	CcSEcCtD
Tolvaptan—Syncope—Dexamethasone—multiple sclerosis	0.000399	0.0023	CcSEcCtD
Tolvaptan—Shock—Triamcinolone—multiple sclerosis	0.000394	0.00227	CcSEcCtD
Tolvaptan—Shock—Methylprednisolone—multiple sclerosis	0.000393	0.00226	CcSEcCtD
Tolvaptan—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000391	0.00225	CcSEcCtD
Tolvaptan—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000391	0.00225	CcSEcCtD
Tolvaptan—Loss of consciousness—Betamethasone—multiple sclerosis	0.000391	0.00225	CcSEcCtD
Tolvaptan—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000391	0.00225	CcSEcCtD
Tolvaptan—Nausea—Azathioprine—multiple sclerosis	0.00039	0.00224	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000388	0.00279	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCR1—multiple sclerosis	0.000388	0.00279	CbGpPWpGaD
Tolvaptan—Skin disorder—Methylprednisolone—multiple sclerosis	0.000388	0.00223	CcSEcCtD
Tolvaptan—Malnutrition—Prednisone—multiple sclerosis	0.000387	0.00223	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—GPR65—multiple sclerosis	0.000385	0.00277	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000385	0.00277	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCR1—multiple sclerosis	0.000385	0.00277	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—GPR65—multiple sclerosis	0.000383	0.00275	CbGpPWpGaD
Tolvaptan—Asthenia—Mitoxantrone—multiple sclerosis	0.00038	0.00219	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000375	0.00269	CbGpPWpGaD
Tolvaptan—Discomfort—Betamethasone—multiple sclerosis	0.000374	0.00215	CcSEcCtD
Tolvaptan—Discomfort—Dexamethasone—multiple sclerosis	0.000374	0.00215	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—LINGO1—multiple sclerosis	0.000373	0.00268	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000372	0.00267	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—LINGO1—multiple sclerosis	0.00037	0.00266	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCL10—multiple sclerosis	0.000368	0.00264	CbGpPWpGaD
Tolvaptan—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000367	0.00211	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CXCL10—multiple sclerosis	0.000365	0.00262	CbGpPWpGaD
Tolvaptan—Urethral disorder—Methotrexate—multiple sclerosis	0.000364	0.0021	CcSEcCtD
Tolvaptan—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000363	0.00209	CcSEcCtD
Tolvaptan—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000363	0.00209	CcSEcCtD
Tolvaptan—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000363	0.00209	CcSEcCtD
Tolvaptan—Ill-defined disorder—Prednisone—multiple sclerosis	0.000359	0.00207	CcSEcCtD
Tolvaptan—Feeling abnormal—Prednisolone—multiple sclerosis	0.000358	0.00206	CcSEcCtD
Tolvaptan—Shock—Betamethasone—multiple sclerosis	0.000357	0.00206	CcSEcCtD
Tolvaptan—Shock—Dexamethasone—multiple sclerosis	0.000357	0.00206	CcSEcCtD
Tolvaptan—Nervous system disorder—Betamethasone—multiple sclerosis	0.000356	0.00205	CcSEcCtD
Tolvaptan—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000356	0.00205	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL13—multiple sclerosis	0.000353	0.00253	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CCR1—multiple sclerosis	0.000353	0.00253	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000351	0.00252	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL13—multiple sclerosis	0.00035	0.00251	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCR1—multiple sclerosis	0.00035	0.00251	CbGpPWpGaD
Tolvaptan—Malaise—Prednisone—multiple sclerosis	0.000349	0.00201	CcSEcCtD
Tolvaptan—Syncope—Prednisone—multiple sclerosis	0.000347	0.002	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000347	0.00249	CbGpPWpGaD
Tolvaptan—Anorexia—Betamethasone—multiple sclerosis	0.000346	0.00199	CcSEcCtD
Tolvaptan—Anorexia—Dexamethasone—multiple sclerosis	0.000346	0.00199	CcSEcCtD
Tolvaptan—Cardiac disorder—Methotrexate—multiple sclerosis	0.000345	0.00199	CcSEcCtD
Tolvaptan—Loss of consciousness—Prednisone—multiple sclerosis	0.00034	0.00196	CcSEcCtD
Tolvaptan—Angiopathy—Methotrexate—multiple sclerosis	0.000337	0.00194	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000337	0.00242	CbGpPWpGaD
Tolvaptan—Immune system disorder—Methotrexate—multiple sclerosis	0.000336	0.00193	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000335	0.00193	CcSEcCtD
Tolvaptan—Headache—Mitoxantrone—multiple sclerosis	0.000332	0.00191	CcSEcCtD
Tolvaptan—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00033	0.0019	CcSEcCtD
Tolvaptan—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000329	0.00189	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000327	0.00189	CcSEcCtD
Tolvaptan—Discomfort—Prednisone—multiple sclerosis	0.000326	0.00188	CcSEcCtD
Tolvaptan—Malnutrition—Methotrexate—multiple sclerosis	0.000324	0.00186	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—TAGAP—multiple sclerosis	0.000323	0.00232	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000322	0.00231	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TAGAP—multiple sclerosis	0.000321	0.0023	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Prednisolone—multiple sclerosis	0.00032	0.00185	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.00032	0.0023	CbGpPWpGaD
Tolvaptan—Dysgeusia—Methotrexate—multiple sclerosis	0.000317	0.00183	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL5—multiple sclerosis	0.000317	0.00227	CbGpPWpGaD
Tolvaptan—Body temperature increased—Triamcinolone—multiple sclerosis	0.000316	0.00182	CcSEcCtD
Tolvaptan—Anaphylactic shock—Prednisone—multiple sclerosis	0.000316	0.00182	CcSEcCtD
Tolvaptan—Decreased appetite—Dexamethasone—multiple sclerosis	0.000315	0.00182	CcSEcCtD
Tolvaptan—Decreased appetite—Betamethasone—multiple sclerosis	0.000315	0.00182	CcSEcCtD
Tolvaptan—Nausea—Mitoxantrone—multiple sclerosis	0.000315	0.00181	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCL5—multiple sclerosis	0.000314	0.00226	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000313	0.0018	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000313	0.0018	CcSEcCtD
Tolvaptan—Shock—Prednisone—multiple sclerosis	0.000311	0.00179	CcSEcCtD
Tolvaptan—Nervous system disorder—Prednisone—multiple sclerosis	0.00031	0.00178	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000307	0.00221	CbGpPWpGaD
Tolvaptan—Skin disorder—Prednisone—multiple sclerosis	0.000307	0.00177	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000303	0.00218	CbGpPWpGaD
Tolvaptan—Anorexia—Prednisone—multiple sclerosis	0.000301	0.00173	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methotrexate—multiple sclerosis	0.0003	0.00173	CcSEcCtD
Tolvaptan—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000299	0.00172	CcSEcCtD
Tolvaptan—Feeling abnormal—Betamethasone—multiple sclerosis	0.000299	0.00172	CcSEcCtD
Tolvaptan—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000295	0.0017	CcSEcCtD
Tolvaptan—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000294	0.00169	CcSEcCtD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000293	0.0021	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000293	0.0021	CbGpPWpGaD
Tolvaptan—Malaise—Methotrexate—multiple sclerosis	0.000292	0.00168	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000291	0.00209	CbGpPWpGaD
Tolvaptan—Dizziness—Prednisolone—multiple sclerosis	0.000288	0.00166	CcSEcCtD
Tolvaptan—Asthenia—Triamcinolone—multiple sclerosis	0.000287	0.00165	CcSEcCtD
Tolvaptan—Body temperature increased—Betamethasone—multiple sclerosis	0.000287	0.00165	CcSEcCtD
Tolvaptan—Body temperature increased—Dexamethasone—multiple sclerosis	0.000287	0.00165	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000286	0.00206	CbGpPWpGaD
Tolvaptan—Asthenia—Methylprednisolone—multiple sclerosis	0.000286	0.00165	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CCR5—multiple sclerosis	0.000285	0.00205	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000284	0.00204	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CCR5—multiple sclerosis	0.000283	0.00203	CbGpPWpGaD
Tolvaptan—Pruritus—Triamcinolone—multiple sclerosis	0.000283	0.00163	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—S1PR1—multiple sclerosis	0.000283	0.00203	CbGpPWpGaD
Tolvaptan—Pruritus—Methylprednisolone—multiple sclerosis	0.000282	0.00163	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—S1PR1—multiple sclerosis	0.00028	0.00201	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000277	0.00199	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GPC5—multiple sclerosis	0.000275	0.00197	CbGpPWpGaD
Tolvaptan—Decreased appetite—Prednisone—multiple sclerosis	0.000275	0.00158	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000274	0.00158	CcSEcCtD
Tolvaptan—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000273	0.00157	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—GPC5—multiple sclerosis	0.000273	0.00196	CbGpPWpGaD
Tolvaptan—Headache—Prednisolone—multiple sclerosis	0.000272	0.00157	CcSEcCtD
Tolvaptan—Discomfort—Methotrexate—multiple sclerosis	0.000272	0.00157	CcSEcCtD
Tolvaptan—Constipation—Prednisone—multiple sclerosis	0.00027	0.00156	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000267	0.00192	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000266	0.00191	CbGpPWpGaD
Tolvaptan—Dizziness—Triamcinolone—multiple sclerosis	0.000265	0.00152	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000264	0.0019	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000264	0.00152	CcSEcCtD
Tolvaptan—Dizziness—Methylprednisolone—multiple sclerosis	0.000264	0.00152	CcSEcCtD
Tolvaptan—Feeling abnormal—Prednisone—multiple sclerosis	0.00026	0.0015	CcSEcCtD
Tolvaptan—Asthenia—Dexamethasone—multiple sclerosis	0.00026	0.0015	CcSEcCtD
Tolvaptan—Asthenia—Betamethasone—multiple sclerosis	0.00026	0.0015	CcSEcCtD
Tolvaptan—Nervous system disorder—Methotrexate—multiple sclerosis	0.000259	0.00149	CcSEcCtD
Tolvaptan—Nausea—Prednisolone—multiple sclerosis	0.000258	0.00149	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000257	0.00185	CbGpPWpGaD
Tolvaptan—Pruritus—Betamethasone—multiple sclerosis	0.000257	0.00148	CcSEcCtD
Tolvaptan—Pruritus—Dexamethasone—multiple sclerosis	0.000257	0.00148	CcSEcCtD
Tolvaptan—Skin disorder—Methotrexate—multiple sclerosis	0.000257	0.00148	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000255	0.00183	CbGpPWpGaD
Tolvaptan—Anorexia—Methotrexate—multiple sclerosis	0.000252	0.00145	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL3—multiple sclerosis	0.000251	0.0018	CbGpPWpGaD
Tolvaptan—Headache—Triamcinolone—multiple sclerosis	0.000251	0.00144	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCR2—multiple sclerosis	0.00025	0.0018	CbGpPWpGaD
Tolvaptan—Headache—Methylprednisolone—multiple sclerosis	0.00025	0.00144	CcSEcCtD
Tolvaptan—Body temperature increased—Prednisone—multiple sclerosis	0.00025	0.00144	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.00025	0.00179	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCL3—multiple sclerosis	0.000249	0.00179	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCR2—multiple sclerosis	0.000248	0.00178	CbGpPWpGaD
Tolvaptan—Diarrhoea—Betamethasone—multiple sclerosis	0.000248	0.00143	CcSEcCtD
Tolvaptan—Diarrhoea—Dexamethasone—multiple sclerosis	0.000248	0.00143	CcSEcCtD
Tolvaptan—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000245	0.00176	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000245	0.00176	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTGER4—multiple sclerosis	0.000242	0.00174	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000241	0.00173	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000241	0.00173	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.00024	0.00173	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RGS1—multiple sclerosis	0.00024	0.00172	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTGER4—multiple sclerosis	0.00024	0.00172	CbGpPWpGaD
Tolvaptan—Dizziness—Dexamethasone—multiple sclerosis	0.00024	0.00138	CcSEcCtD
Tolvaptan—Dizziness—Betamethasone—multiple sclerosis	0.00024	0.00138	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—RGS1—multiple sclerosis	0.000238	0.00171	CbGpPWpGaD
Tolvaptan—Nausea—Triamcinolone—multiple sclerosis	0.000238	0.00137	CcSEcCtD
Tolvaptan—Nausea—Methylprednisolone—multiple sclerosis	0.000237	0.00137	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000236	0.00169	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000236	0.00169	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000234	0.00168	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Prednisone—multiple sclerosis	0.000233	0.00134	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—CXCR3—multiple sclerosis	0.000232	0.00166	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000231	0.00166	CbGpPWpGaD
Tolvaptan—Decreased appetite—Methotrexate—multiple sclerosis	0.00023	0.00132	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000229	0.00165	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CNR1—multiple sclerosis	0.000229	0.00165	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000228	0.00131	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—GPR65—multiple sclerosis	0.000228	0.00164	CbGpPWpGaD
Tolvaptan—Headache—Dexamethasone—multiple sclerosis	0.000227	0.00131	CcSEcCtD
Tolvaptan—Headache—Betamethasone—multiple sclerosis	0.000227	0.00131	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CCR2—multiple sclerosis	0.000227	0.00163	CbGpPWpGaD
Tolvaptan—Asthenia—Prednisone—multiple sclerosis	0.000227	0.00131	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—GPR65—multiple sclerosis	0.000226	0.00162	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCR2—multiple sclerosis	0.000226	0.00162	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000224	0.00161	CbGpPWpGaD
Tolvaptan—Pruritus—Prednisone—multiple sclerosis	0.000224	0.00129	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000224	0.00161	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—POMC—multiple sclerosis	0.000223	0.0016	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—POMC—multiple sclerosis	0.000221	0.00159	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CCL2—multiple sclerosis	0.000218	0.00157	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Methotrexate—multiple sclerosis	0.000218	0.00125	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CCL2—multiple sclerosis	0.000217	0.00156	CbGpPWpGaD
Tolvaptan—Diarrhoea—Prednisone—multiple sclerosis	0.000216	0.00125	CcSEcCtD
Tolvaptan—Nausea—Betamethasone—multiple sclerosis	0.000216	0.00124	CcSEcCtD
Tolvaptan—Nausea—Dexamethasone—multiple sclerosis	0.000216	0.00124	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—FAS—multiple sclerosis	0.000211	0.00152	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	0.00021	0.00151	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CNR1—multiple sclerosis	0.00021	0.00151	CbGpPWpGaD
Tolvaptan—Dizziness—Prednisone—multiple sclerosis	0.000209	0.0012	CcSEcCtD
Tolvaptan—Body temperature increased—Methotrexate—multiple sclerosis	0.000209	0.0012	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL13—multiple sclerosis	0.000208	0.0015	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCR1—multiple sclerosis	0.000208	0.0015	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CNR1—multiple sclerosis	0.000208	0.00149	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000208	0.00149	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	0.000208	0.00149	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL13—multiple sclerosis	0.000207	0.00148	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCR1—multiple sclerosis	0.000207	0.00148	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000206	0.00148	CbGpPWpGaD
Tolvaptan—Headache—Prednisone—multiple sclerosis	0.000198	0.00114	CcSEcCtD
Tolvaptan—Hypersensitivity—Methotrexate—multiple sclerosis	0.000195	0.00112	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.00019	0.00136	CbGpPWpGaD
Tolvaptan—Asthenia—Methotrexate—multiple sclerosis	0.00019	0.00109	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL10—multiple sclerosis	0.000189	0.00136	CbGpPWpGaD
Tolvaptan—Nausea—Prednisone—multiple sclerosis	0.000188	0.00108	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL10—multiple sclerosis	0.000187	0.00135	CbGpPWpGaD
Tolvaptan—Pruritus—Methotrexate—multiple sclerosis	0.000187	0.00108	CcSEcCtD
Tolvaptan—Diarrhoea—Methotrexate—multiple sclerosis	0.000181	0.00104	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCL5—multiple sclerosis	0.000179	0.00128	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCL5—multiple sclerosis	0.000178	0.00128	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CD80—multiple sclerosis	0.000175	0.00126	CbGpPWpGaD
Tolvaptan—Dizziness—Methotrexate—multiple sclerosis	0.000175	0.00101	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000172	0.00123	CbGpPWpGaD
Tolvaptan—Headache—Methotrexate—multiple sclerosis	0.000165	0.000953	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL5—multiple sclerosis	0.000163	0.00117	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCL5—multiple sclerosis	0.000161	0.00116	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CCR5—multiple sclerosis	0.000161	0.00116	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CCR5—multiple sclerosis	0.00016	0.00115	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000159	0.00114	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000158	0.00113	CbGpPWpGaD
Tolvaptan—Nausea—Methotrexate—multiple sclerosis	0.000157	0.000904	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000156	0.00112	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000156	0.00112	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000152	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCL3—multiple sclerosis	0.000148	0.00107	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCL3—multiple sclerosis	0.000147	0.00106	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CCR5—multiple sclerosis	0.000146	0.00105	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCR5—multiple sclerosis	0.000145	0.00104	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL2RA—multiple sclerosis	0.000144	0.00104	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL2RA—multiple sclerosis	0.000143	0.00103	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTGER4—multiple sclerosis	0.000143	0.00103	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTGER4—multiple sclerosis	0.000142	0.00102	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000141	0.00101	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PGR—multiple sclerosis	0.000141	0.00101	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PGR—multiple sclerosis	0.00014	0.001	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	0.000139	0.000995	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCR3—multiple sclerosis	0.000138	0.000991	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCR3—multiple sclerosis	0.000137	0.000984	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CD28—multiple sclerosis	0.000137	0.000981	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CD28—multiple sclerosis	0.000136	0.000974	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCR2—multiple sclerosis	0.000134	0.000964	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCR2—multiple sclerosis	0.000133	0.000957	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000128	0.000918	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—POMC—multiple sclerosis	0.000126	0.000905	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—POMC—multiple sclerosis	0.000125	0.000898	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CNR1—multiple sclerosis	0.000124	0.000889	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	0.000124	0.000888	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL2—multiple sclerosis	0.000123	0.000884	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CNR1—multiple sclerosis	0.000123	0.000883	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000122	0.000875	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000118	0.000849	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—POMC—multiple sclerosis	0.000114	0.000822	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—POMC—multiple sclerosis	0.000114	0.000816	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CCL2—multiple sclerosis	0.000112	0.000804	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL10—multiple sclerosis	0.000112	0.000801	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CCL2—multiple sclerosis	0.000111	0.000798	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL10—multiple sclerosis	0.000111	0.000795	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000104	0.000749	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000104	0.000744	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—TYK2—multiple sclerosis	0.000102	0.00073	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—TYK2—multiple sclerosis	0.000101	0.000725	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CD86—multiple sclerosis	9.75e-05	0.0007	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CD86—multiple sclerosis	9.68e-05	0.000695	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SRM—multiple sclerosis	9.65e-05	0.000693	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	9.61e-05	0.00069	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCL5—multiple sclerosis	9.6e-05	0.000689	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCL5—multiple sclerosis	9.53e-05	0.000684	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	9.35e-05	0.000671	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—IL2—multiple sclerosis	9.31e-05	0.000669	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—IL2—multiple sclerosis	9.25e-05	0.000664	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TNF—multiple sclerosis	8.97e-05	0.000644	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SPP1—multiple sclerosis	8.89e-05	0.000638	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SPP1—multiple sclerosis	8.83e-05	0.000634	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCR5—multiple sclerosis	8.65e-05	0.000621	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCR5—multiple sclerosis	8.59e-05	0.000617	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL2RA—multiple sclerosis	8.52e-05	0.000612	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL2RA—multiple sclerosis	8.46e-05	0.000608	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL2—multiple sclerosis	8.46e-05	0.000607	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL2—multiple sclerosis	8.4e-05	0.000603	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	8.27e-05	0.000593	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—APOE—multiple sclerosis	7.87e-05	0.000565	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—APOE—multiple sclerosis	7.81e-05	0.000561	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CD80—multiple sclerosis	7.11e-05	0.000511	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CD80—multiple sclerosis	7.06e-05	0.000507	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP27B1—multiple sclerosis	6.8e-05	0.000488	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP24A1—multiple sclerosis	6.8e-05	0.000488	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—POMC—multiple sclerosis	6.76e-05	0.000485	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—POMC—multiple sclerosis	6.71e-05	0.000482	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCL2—multiple sclerosis	6.61e-05	0.000475	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCL2—multiple sclerosis	6.57e-05	0.000471	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—MAPK1—multiple sclerosis	6.47e-05	0.000465	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—MAPK1—multiple sclerosis	6.42e-05	0.000461	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GPC5—multiple sclerosis	6.22e-05	0.000446	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TYK2—multiple sclerosis	6.01e-05	0.000431	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TYK2—multiple sclerosis	5.96e-05	0.000428	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SRM—multiple sclerosis	5.94e-05	0.000427	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.51e-05	0.000395	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—RRM1—multiple sclerosis	5.15e-05	0.00037	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL2—multiple sclerosis	5e-05	0.000359	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL6—multiple sclerosis	4.97e-05	0.000357	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL2—multiple sclerosis	4.96e-05	0.000356	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL6—multiple sclerosis	4.94e-05	0.000354	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	4.75e-05	0.000341	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	4.74e-05	0.00034	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MMP9—multiple sclerosis	4.73e-05	0.00034	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MMP9—multiple sclerosis	4.7e-05	0.000337	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	4.65e-05	0.000334	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	4.43e-05	0.000318	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—STAT3—multiple sclerosis	4.2e-05	0.000302	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.19e-05	0.000301	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.19e-05	0.000301	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—STAT3—multiple sclerosis	4.17e-05	0.0003	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MYC—multiple sclerosis	3.91e-05	0.000281	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TGFB1—multiple sclerosis	3.9e-05	0.00028	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MYC—multiple sclerosis	3.88e-05	0.000279	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TGFB1—multiple sclerosis	3.87e-05	0.000278	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.83e-05	0.000275	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MAPK1—multiple sclerosis	3.82e-05	0.000274	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MAPK1—multiple sclerosis	3.79e-05	0.000273	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.17e-05	0.000228	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.98e-05	0.000214	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—BCHE—multiple sclerosis	2.96e-05	0.000212	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL6—multiple sclerosis	2.94e-05	0.000211	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL6—multiple sclerosis	2.92e-05	0.000209	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.82e-05	0.000131	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—APOE—multiple sclerosis	1.78e-05	0.000128	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—POMC—multiple sclerosis	1.53e-05	0.00011	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALB—multiple sclerosis	1.39e-05	0.0001	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—APOE—multiple sclerosis	1.1e-05	7.87e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—POMC—multiple sclerosis	9.42e-06	6.76e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALB—multiple sclerosis	8.59e-06	6.17e-05	CbGpPWpGaD
